Literature DB >> 17540175

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Surbhi Gupta1, Antoine R Ramjaun, Paula Haiko, Yihua Wang, Patricia H Warne, Barbara Nicke, Emma Nye, Gordon Stamp, Kari Alitalo, Julian Downward.   

Abstract

Ras proteins signal through direct interaction with a number of effector enzymes, including type I phosphoinositide (PI) 3-kinases. Although the ability of Ras to control PI 3-kinase has been well established in manipulated cell culture models, evidence for a role of the interaction of endogenous Ras with PI 3-kinase in normal and malignant cell growth in vivo has been lacking. Here we generate mice with mutations in the Pi3kca gene encoding the catalytic p110alpha isoform that block its interaction with Ras. Cells from these mice show proliferative defects and selective disruption of signaling from growth factors to PI 3-kinase. The mice display defective development of the lymphatic vasculature, resulting in perinatal appearance of chylous ascites. Most importantly, they are highly resistant to endogenous Ras oncogene-induced tumorigenesis. The interaction of Ras with p110alpha is thus required in vivo for certain normal growth factor signaling and for Ras-driven tumor formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540175     DOI: 10.1016/j.cell.2007.03.051

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  270 in total

1.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

2.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

3.  Cooperative activation of PI3K by Ras and Rho family small GTPases.

Authors:  Hee Won Yang; Min-Gyoung Shin; Sangkyu Lee; Jeong-Rae Kim; Wei Sun Park; Kwang-Hyun Cho; Tobias Meyer; Won Do Heo
Journal:  Mol Cell       Date:  2012-06-07       Impact factor: 17.970

Review 4.  Cellular responses to extracellular guidance cues.

Authors:  Anastacia Berzat; Alan Hall
Journal:  EMBO J       Date:  2010-08-18       Impact factor: 11.598

Review 5.  Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.

Authors:  James M Cleary; Geoffrey I Shapiro
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

Review 6.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

7.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

8.  Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.

Authors:  Braden D Siempelkamp; Manoj K Rathinaswamy; Meredith L Jenkins; John E Burke
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

9.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

Review 10.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.